【丽珠医药(01513.HK)拟斥资约15.87亿元收购一家越南制药公司64.81%股权】丽珠医药(01513.HK)公布,于2025年5月22日,该公司间接全资附属LIAN SGP HOLDING PTE. LTD.拟向SK Investment、Sunrise及KBA收购Imexpharm Corporation已发行股份的64.81%,总现金代价为 5,730,815,426,000越南盾(按协议签署当日汇率换算,约为人民币15.87亿元,港币17.28 亿元)。交割后,目标公司将成为本公司一间间接非全资附属公司,其财务业绩将并入该集团财务报表。

金融界
22 May
丽珠医药(01513.HK)公布,于2025年5月22日,该公司间接全资附属LIAN SGP HOLDING PTE. LTD.拟向SK Investment、Sunrise及KBA收购Imexpharm Corporation已发行股份的64.81%,总现金代价为 5,730,815,426,000越南盾(按协议签署当日汇率换算,约为人民币15.87亿元,港币17.28 亿元)。交割后,目标公司将成为本公司一间间接非全资附属公司,其财务业绩将并入该集团财务报表。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10